Sofosbuvir, a NS5B Polymerase Inhibitor in the treatment of Hepatitis C: A Review of its Clinical Potential

There are now major changes occurring in the treatment of chronic hepatitis C (HCV). The effectiveness and tolerability of traditional interferon-based therapy have been constrained, and a number of direct acting antiviral (DAA) medications are being developed. Phase II and III interferon-free clinical trials have now thoroughly assessed sofosbuvir (GS-7977), an HCV NS5B nucleotide polymerase inhibitor. The clinical potential of sofosbuvir in the treatment of HCV is the main topic of this review. Although sustained virological response (SVR) varies by virus genotype, sofosbuvir has a pan-genotypic effect on HCV, according to phase III clinical trials. Both dual therapy with ribavirin and triple therapy with either NS5A inhibitors or a protease inhibitor have been investigated for sofosbuvir. There have been reports of high SVR rates. Both cirrhotic and noncirrhotic patients have shown excellent safety profiles with no problems of viral resistance, and high rates of SVR have been documented with these interferon-free combinations, especially with genotypes 1 and 2. It is now possible to treat HCV once daily without the use of interferon.